Premature Ejaculation Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -
PREMATURE EJACULATION THERAPEUTICS PIPELINE INSIGHTS
• Premature ejaculation is a kind of sexual dysfunction that occurs when a man ejaculates sooner than expected by the partner during sexual intercourse.
• The predisposing factors include erectile dysfunction, stress and certain medications that influence the action of chemical messengers in the brain (psychotropics) may contribute to premature ejaculation.
• Treatment includes topical anesthetic creams and antidepressants. Therapeutic drugs, home remedies, and exercises are precise treatments for premature ejaculation.
• The overall premature ejaculation treatment market has attested the increased use of off-label drugs belonging to different drug classes such as selective serotonin reuptake inhibitors (SSRIs) like fluvoxamine, paroxetine, sertraline, and fluoxetine and PDE5 inhibitors like Cialis, Viagra, and Levitra. Forthcoming PE drugs include Priligy and topically applied PSD502/TEMPE. The market for PE therapeutics is highly competitive, as only Priligy is approved for treatment.
• Pharmacological alteration of the ejaculatory response in patients with the condition is represented as a novel approach for the premature ejaculation treatment, and this will cause the steady replacement of psychosexual counseling which was previously regarded as the cornerstone of early ejaculation treatment.
• Also, the drugs in this class are known to exhibit high efficacy with minor side effects. The clinical pipeline of PE therapeutics is found to have few studies, and more percentage of reviews are exposed to in phase II stage of clinical trial development. CTC Bio is involved in the process of developing CDFR0812 as an adrenergic uptake inhibitor for the treatment of the disease. Ixchelsis Ltd. is developing IX-01 (oxytocin receptor antagonist). Ampio Pharmaceuticals entered in a strategic agreement with Ethypharm S.A. for the manufacturing of Zertane, Absorption Pharmaceuticals LLC in important collaboration with Kaiser Permanente has initiated clinical trials to evaluate the efficacy of Promescent lidocaine spray for men with premature ejaculation (PE). Prolong is a device from InnovaDerma that is an FDA approved device is used in the premature ejaculation treatment. Launches of devices are expected to restrain the growth of the global early ejaculation treatment market.
• For instance, Regent Pacific Group Limited, a Hong Kong-based investment group, launched its product, Fortin. Fortacin (topical spray) contains low doses of two anesthetics like lidocaine and prilocaine and is indicated for the treatment of premature ejaculation.
• A high strain of PE prevalence and associated chronic condition. The high-risk factor of occurrence is expected to be the key market driver for the premature ejaculation market in both developing and developed countries.
• Low effectiveness of non-pharmacological treatment and full accessibility to generic off-label drugs and OTC drugs are the prime factors that will boost market growth during the next decade.
• Likewise, pharmaceutical advances in PE drug formulation technology, the launch of premature ejaculation treatment awareness campaigns, insistence on the clinical advancement of love hormone receptor antagonists, and are known to be the latest trends that will positively impact the market.
• Premature ejaculation is a kind of sexual dysfunction that occurs when a man ejaculates sooner than expected by the partner during sexual intercourse.
• The predisposing factors include erectile dysfunction, stress and certain medications that influence the action of chemical messengers in the brain (psychotropics) may contribute to premature ejaculation.
• Treatment includes topical anesthetic creams and antidepressants. Therapeutic drugs, home remedies, and exercises are precise treatments for premature ejaculation.
• The overall premature ejaculation treatment market has attested the increased use of off-label drugs belonging to different drug classes such as selective serotonin reuptake inhibitors (SSRIs) like fluvoxamine, paroxetine, sertraline, and fluoxetine and PDE5 inhibitors like Cialis, Viagra, and Levitra. Forthcoming PE drugs include Priligy and topically applied PSD502/TEMPE. The market for PE therapeutics is highly competitive, as only Priligy is approved for treatment.
• Pharmacological alteration of the ejaculatory response in patients with the condition is represented as a novel approach for the premature ejaculation treatment, and this will cause the steady replacement of psychosexual counseling which was previously regarded as the cornerstone of early ejaculation treatment.
• Also, the drugs in this class are known to exhibit high efficacy with minor side effects. The clinical pipeline of PE therapeutics is found to have few studies, and more percentage of reviews are exposed to in phase II stage of clinical trial development. CTC Bio is involved in the process of developing CDFR0812 as an adrenergic uptake inhibitor for the treatment of the disease. Ixchelsis Ltd. is developing IX-01 (oxytocin receptor antagonist). Ampio Pharmaceuticals entered in a strategic agreement with Ethypharm S.A. for the manufacturing of Zertane, Absorption Pharmaceuticals LLC in important collaboration with Kaiser Permanente has initiated clinical trials to evaluate the efficacy of Promescent lidocaine spray for men with premature ejaculation (PE). Prolong is a device from InnovaDerma that is an FDA approved device is used in the premature ejaculation treatment. Launches of devices are expected to restrain the growth of the global early ejaculation treatment market.
• For instance, Regent Pacific Group Limited, a Hong Kong-based investment group, launched its product, Fortin. Fortacin (topical spray) contains low doses of two anesthetics like lidocaine and prilocaine and is indicated for the treatment of premature ejaculation.
• A high strain of PE prevalence and associated chronic condition. The high-risk factor of occurrence is expected to be the key market driver for the premature ejaculation market in both developing and developed countries.
• Low effectiveness of non-pharmacological treatment and full accessibility to generic off-label drugs and OTC drugs are the prime factors that will boost market growth during the next decade.
• Likewise, pharmaceutical advances in PE drug formulation technology, the launch of premature ejaculation treatment awareness campaigns, insistence on the clinical advancement of love hormone receptor antagonists, and are known to be the latest trends that will positively impact the market.
